FATE
FATE THERAPEUTICS INC
$2.06
+4.57%
$240.1M
No data for this timeframe.
Vol
Market Cap$240.1M
Cap SizeMicro Cap
Analyst ConsensusBuy (61%)
Inst. Holders50 funds
Inst. Value$44.0M
Inst. Activity13 buys / 4 sells
Insider Activity0B / 2S
Insider Net $-$102.6K
Reddit Sentiment33° Cool
SEC Reports4
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001434316·Prev Close $1.97
Recent Activity
Jun 12, 2026
short_volume
Short Volume: FATE — 62.2% short (1.4M / 2.3M)
Short: 1,404,693 | Exempt: 2,829 | TRF Vol: 2,259,942 | Short Ratio: 62.2% | Off-exchange volume (da
Jun 11, 2026
SEC
FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M
INST-CLUSTER — Impact 5/10
Jun 4, 2026
SEC
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli
8-K — Impact 4/10
Jun 1, 2026
Press
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid
Impact 6/10
May 20, 2026
Insider
Valamehr Bahram sold 28,946 shares
President and CEO @ $1.88 ($54.5K)
May 20, 2026
Insider
TAHL CINDY sold 25,590 shares
See Remarks @ $1.88 ($48.1K)
May 13, 2026
SEC
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in
8-K — Impact 5/10
May 6, 2026
Insider
TAHL CINDY acquired via exercise 122,220 shares
See Remarks @ $1.32 ($161.3K)
Price Targets
$5.41
+162.7% upside
Strong Buy
Current $2.06
Low $2.20
Median $6.00
High $8.00
9 analysts
$2.20
$8.00
Analyst Ratings
5Strong Buy
6Buy
7Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 | $-0.28 — $-0.22 | 11% YoY | 9 |
| Next Q | $-0.26 | $-0.31 — $-0.17 | 2% YoY | 9 |
| Current FY | $-1.02 | $-1.21 — $-0.77 | 11% YoY | 8 |
| Next FY | $-0.92 ▲ +11.9% | $-1.37 — $-0.59 | 10% YoY | 8 |
Latest Reports
BEARISH
INST-CLUSTER
5/10
FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M
Jun 11, 2026
NEUTRAL
8-K
4/10
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli
Jun 4, 2026
BULLISH
Press
6/10
Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $12.1M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.0M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5.0M | — |
| TWO SIGMA INVESTMENTS, LP | $4.2M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $3.6M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Valamehr Bahram | SELL | $54.5K |
| May 20, 2026 | TAHL CINDY | SELL | $48.1K |
| May 6, 2026 | TAHL CINDY | M | $161.3K |
| May 5, 2026 | RASTETTER WILLIAM | M | $42.3K |
| May 5, 2026 | EPSTEIN ROBERT | M | $42.3K |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $44.0M total value (36,660,417 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 13 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10,068,614 | $12.1M | 27.5% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4,192,063 | $5.0M | 11.4% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,134,585 | $5.0M | 11.3% | — |
| 4 | TWO SIGMA INVESTMENTS, LP | 3,466,786 | $4.2M | 9.5% | ADD +92.5% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 2,974,683 | $3.6M | 8.1% | ADD +26.0% |
| 6 | STATE STREET CORP | 2,263,173 | $2.7M | 6.2% | — |
| 7 | GOLDMAN SACHS GROUP INC | 1,327,757 | $1.6M | 3.6% | — |
| 8 | CITADEL ADVISORS LLC | 942,926 | $1.1M | 2.6% | NEAR_EXIT -81.9% |
| 9 | DIMENSIONAL FUND ADVISORS LP | 883,790 | $1.1M | 2.4% | TRIM -44.0% |
| 10 | MORGAN STANLEY | 767,748 | $921.3K | 2.1% | TRIM -61.8% |
| 11 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 756,273 | $907.5K | 2.1% | — |
| 12 | VANGUARD FIDUCIARY TRUST CO | 653,761 | $784.5K | 1.8% | — |
| 13 | Connor, Clark & Lunn Investment Management Ltd. | 469,785 | $563.7K | 1.3% | DOUBLED +322.4% |
| 14 | Invesco Ltd. | 375,886 | $451.1K | 1.0% | — |
| 15 | Nuveen, LLC | 339,073 | $406.9K | 0.9% | — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 298,496 | $358.2K | 0.8% | — |
| 17 | Woodline Partners LP | 238,650 | $286.4K | 0.7% | TRIM -33.1% |
| 18 | Assenagon Asset Management S.A. | 190,252 | $228.3K | 0.5% | ADD +28.0% |
| 19 | BANK OF AMERICA CORP /DE/ | 188,564 | $226.3K | 0.5% | — |
| 20 | ALLIANCEBERNSTEIN L.P. | 187,700 | $184.4K | 0.4% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 2,360,881 | 2,974,683 | +26.0% | $3.6M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 1,577,478 | 883,790 | -44.0% | $1.1M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 111,227 | 469,785 | +322.4% | $563.7K | 2026-Q1 |
| Woodline Partners LP | TRIM | 356,650 | 238,650 | -33.1% | $286.4K | 2026-Q1 |
| Assenagon Asset Management S.A. | ADD | 148,653 | 190,252 | +28.0% | $228.3K | 2026-Q1 |
| CWM, LLC | DOUBLED | 51,789 | 139,796 | +169.9% | $167.8K | 2026-Q1 |
| SEI INVESTMENTS CO | DOUBLED | 67,643 | 138,580 | +104.9% | $166.3K | 2026-Q1 |
| Cerity Partners LLC | DOUBLED | 52,489 | 113,544 | +116.3% | $136.3K | 2026-Q1 |
| Mariner, LLC | DOUBLED | 14,889 | 98,295 | +560.2% | $117.9K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 34,925 | 71,491 | +104.7% | $87.2K | 2026-Q1 |
| FMR LLC | DOUBLED | 12,756 | 47,590 | +273.1% | $57.1K | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 1,527,986 | 43,119 | -97.2% | $51.7K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 25,534 | 41,880 | +64.0% | $50.2K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 4,431 | 9,305 | +110.0% | $11.2K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 424 | 3,252 | +667.0% | $3.9K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 54,470 | 76,633 | +40.7% | $92.00 | 2026-Q1 |
| HRT FINANCIAL LP | NEAR_EXIT | 48,544 | 10,398 | -78.6% | $12.00 | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,262,515 | 2,360,881 | +87.0% | $2.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 900,757 | 1,734,064 | +92.5% | $1.7M | 2025-Q4 |
| Woodline Partners LP | TRIM | 712,650 | 356,650 | -50.0% | $350.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 133,839 | 172,283 | +28.7% | $169.3K | 2025-Q4 |
| DEUTSCHE BANK AG\ | TRIM | 157,159 | 91,679 | -41.7% | $89.8K | 2025-Q4 |
| CAPTRUST FINANCIAL ADVISORS | ADD | 19,489 | 25,534 | +31.0% | $25.1K | 2025-Q4 |
| PRUDENTIAL FINANCIAL INC | TRIM | 43,191 | 23,160 | -46.4% | $22.8K | 2025-Q4 |
| Mariner, LLC | TRIM | 22,930 | 14,889 | -35.1% | $14.6K | 2025-Q4 |
5 unique insiders with 10 transactions. Net insider value: -$102.6K ($0.00 bought, $102.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Valamehr Bahram | President and CEO | SELL | 28,946 | $1.88 | $54.5K |
| May 20, 2026 | TAHL CINDY | See Remarks | SELL | 25,590 | $1.88 | $48.1K |
| May 6, 2026 | TAHL CINDY | See Remarks | EXERCISE | 122,220 | $1.32 | $161.3K |
| May 5, 2026 | RASTETTER WILLIAM H | Director | EXERCISE | 25,000 | $1.69 | $42.3K |
| May 5, 2026 | EPSTEIN ROBERT S | Director | EXERCISE | 25,000 | $1.69 | $42.3K |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 266,280 | — | — |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 8,977,624 | — | — |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 3,691,324 | — | — |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 266,280 | — | — |
| Apr 20, 2026 | Redmile Group, LLC | Director | J | 162,013 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
BEARISH
INST-CLUSTER
5/10
FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel
Jun 11, 2026
NEUTRAL
8-K
4/10
Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2
Jun 4, 2026
NEUTRAL
8-K
5/10
Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower tha
May 13, 2026
NEUTRAL
DEFA14A
3/10
FATE THERAPEUTICS INC filed a definitive proxy statement for its 2026 annual shareholder meeting, pr
Apr 24, 2026
Current analyst consensus: Buy (61% buy). Based on 18 analysts: 5 strong buy, 6 buy, 7 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.41 mean target
+162.7% upside
Strong Buy (2.08)
$2.20 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $2.06 |
| Target Low | $2.20 |
| Target Mean | $5.41 |
| Target Median | $6.00 |
| Target High | $8.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (2.08) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.28 | $-0.22 | 10.7% | — | 4↑ 0↓ | $0.0B | -50.5% | 9 |
| Next Q 2026-09-30 |
$-0.26 | $-0.31 | $-0.17 | 2.1% | — | 5↑ 0↓ | $0.0B | -41.8% | 9 |
| Current FY 2026-12-31 |
$-1.02 | $-1.21 | $-0.77 | 10.9% | — | 6↑ 0↓ | $0.0B | -35.2% | 8 |
| Next FY 2027-12-31 |
$-0.92 | $-1.37 | $-0.59 | 9.9% | +11.9% | 3↑ 1↓ | $0.0B | 22.4% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.259 | |
| 7d ago | $-0.258 | -0.001 |
| 30d ago | $0.000 | -0.259 |
| 60d ago | $-0.285 | +0.026 |
| 90d ago | $-0.284 | +0.025 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| May 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Apr 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Mar 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Feb 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% | |
| Jan 1, 2026 | 5 | 6 | 7 | 0 | 0 | 61% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Jun 12, 2026
short_volume
Short Volume: FATE — 62.2% short (1.4M / 2.3M)
Short: 1,404,693 | Exempt: 2,829 | TRF Vol: 2,259,942 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: FATE — 58.4% short (0.4M / 0.7M)
Short: 418,467 | Exempt: 110 | TRF Vol: 716,842 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
activist
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company d
Jun 2, 2026
short_volume
Short Volume: FATE — 65.6% short (1.2M / 1.8M)
Short: 1,161,056 | Exempt: 115,578 | TRF Vol: 1,768,736 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
fda
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
<p align="center"><em>FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal
Jun 1, 2026
short_volume
Short Volume: FATE — 62.2% short (2.7M / 4.3M)
Short: 2,703,238 | Exempt: 309,396 | TRF Vol: 4,346,329 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 21, 2026
routine
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
<p>SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bring
May 13, 2026
earnings
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
<p align="center"><em>RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe system
May 11, 2026
fda
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
<p align="center"><em>Single dose treatment of FT819 without conditioning chemotherapy achieves lupus low disease activity state (LLDAS) in active SLE
May 6, 2026
earnings_calendar
FATE Q1 2026 Earnings Scheduled — 2026-05-06
May 1, 2026
other
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
<p>SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bring
Apr 30, 2026
other
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
<p>SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bri
Apr 10, 2026
short_volume
Short Volume: FATE — 75.6% short (0.4M / 0.6M)
Short: 442,749 | Exempt: 0 | TRF Vol: 585,581 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Apr 9, 2026
short_volume
Short Volume: FATE — 55.0% short (0.5M / 0.8M)
Short: 452,418 | Exempt: 0 | TRF Vol: 822,331 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
other
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company